RE: Expectations13 Jun 2020 19:27
Davey
The results that StemprintER is better than Exact sciences offering is based on data from two fully operational cancer hospitals in the UK.
· StemPrintER Outperforms Oncotype DX in analysis with 800+ samples from ER+/HER2- postmenopausal breast cancer patients
· SPARE Model is up to 40-50% more accurate than standard clinical markers in analysis with 1800+ samples for prediction of distant metastasis
It’s also not a handful of tests like we have in preclinical or phase I and II clinical. This is over 2600 samples combined.
The head-to-head comparison of StemPrintER with Oncotype DX was conducted in collaboration with the Royal Marsden Hospital and Queen Mary University in London.
StemprintER is as good to production as can be. Whilst we don’t know the actual clinical setting... if StemprintER was in the two hospitals, there is no way a sub standard testing equipment would be granted space in UK hospitals unless there was Accreditation’s and a robust clinical approved plan to test. The hospitals have either tested 2600+ Samples or given TILS access to those samples and I can almost guarantee that Tils must have done many hundreds prior. They must know it works before they collaborated with the two UK hospitals. Also the Milan oncology dept wouldn’t validate the test scores unless they were privy to first hand testing and data.
Another thing to consider is that the tool/device must be accredited as safe by various bodies before it goes into a hospital if that is where the tests happened. Or if they gave Tils access to samples, that is a lot of approvals and regulatory hurdles they would have to cross. If I approached my local hospital and asked l, give me some samples you can imagine which way the conversation would go.
Granted there may be more approvals needed to sell StemprintER, but to have it in, not one but two hospitals in a live setting or for the two hospitals to provide 2600+ samples must mean it’s fully operational. It’s no good saying oncology DX has given a result but Tils lags weeks behind and then claim to be better. It’s must be on par.
Sorry this is a rushed message, in simple English this doesn’t read like a tool out together with sticky tape and one side of A4 instructions wheel carted into two hospitals or into a lab somewhere in Tils land. It must be close to the finished article. This almost comes across as a phase III type of setting, and tils used asco to let the whole world know they have a better tool. The claims of 20-30% have to stand up otherwise Exact would sue Tils soooo hard they would bankrupt them overnight.
I am willing to wager anyone that Exact have already seen this tool work or will be doing very soon. When a new kid steps on the block and is talking big, you don’t sit back and let him take over. Especially when he’s calling you out by name.
Sign In
Follow the stocks
